These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 38717034

  • 21. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study.
    Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM.
    Helicobacter; 2020 Aug; 25(4):e12694. PubMed ID: 32314519
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X, Tan P, Song L, Lu Z.
    Am J Ther; 2016 Aug; 23(6):e1436-e1441. PubMed ID: 25923229
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H.
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
    Chen XX, Chen YX, Bi HX, Zhao X, Zhang LF, Liu JY, Shi YQ.
    J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
    [Abstract] [Full Text] [Related]

  • 27. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients.
    Cho JH, Jeon SR, Kim HG, Jin SY, Park S.
    J Gastroenterol Hepatol; 2019 Apr; 34(4):700-706. PubMed ID: 30011083
    [Abstract] [Full Text] [Related]

  • 29. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ, Wang XL, Huang XY, Li DZ, Liu G, Wang W, Li DL.
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [Abstract] [Full Text] [Related]

  • 30. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
    Sugimoto M, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T.
    Helicobacter; 2014 Aug; 19(4):312-8. PubMed ID: 24690010
    [Abstract] [Full Text] [Related]

  • 32. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
    Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y.
    Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
    [Abstract] [Full Text] [Related]

  • 33. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
    Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY.
    Dig Dis Sci; 2022 Apr; 67(4):1222-1230. PubMed ID: 33755825
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
    Aktaş B, Başyiğit S, Yüksel O, Akkan T, Atbaşı ST, Uzman M, Yılmaz B, Şimşek G, Nazlıgül Y.
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
    [Abstract] [Full Text] [Related]

  • 39. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [Abstract] [Full Text] [Related]

  • 40. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N.
    World J Gastroenterol; 2015 Jul 14; 21(26):8132-9. PubMed ID: 26185386
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.